Xorazm viloyatida TP53 genidagi Pro72Arg (rs1042522) polimorfizmining mieloproliferativ neoplaziyalar rivojlanishi bilan bogʻliqligi

M.U Jumaboeva

Xorazm viloyati koʻp tarmoqli tibbiyot markazi Respublika ixtisoslashtirilgan gematologiya ilmiy amaliy tibbiyot markazi

M.S Islamov

Xorazm viloyati koʻp tarmoqli tibbiyot markazi Respublika ixtisoslashtirilgan gematologiya ilmiy amaliy tibbiyot markazi

K.T Boboev

Xorazm viloyati koʻp tarmoqli tibbiyot markazi Respublika ixtisoslashtirilgan gematologiya ilmiy amaliy tibbiyot markazi

Keywords: TP53 genining Pro72Arg polimorfizmi, rs1042522, MPN, molekulyar genetika, gen mutatsiyalari va saraton, mieloproliferativ kasalliklar prognozi.

---

Abstract

TP53 genining Pro72Arg (rs1042522) polimorfizmining allelik va genotipik variantlarining mieloproliferativ neoplaziyalar (MPN) rivojlanishiga ta'sirini baholash.

---

References

1. Schulz E, Sill H. The TP53 Pro72Arg SNP in de novo acute myeloid leukemia. Haematologica. 2017 May;102(5): e214-e215. doi: 10.3324/haematol.2017.165019. PMID: 28458254; PMCID: PMC5477628.

2. Mohammad Salman Akhtar, Raed A. Alharbi, Genetic association of TP53 Pro72Arg polymorphism (rs1042522) in Leukemia: An updated meta-analysis of 10 case-control studies, Human Gene, Volume 34, 2022, 201130, ISSN 2773-0441, https://doi.org/10.1016/j.humgen.2022.201130.

3. Tefferi A, Abdelmagid M, Loscocco GG, Fathima S, Begna KH, Al-Kali A, Foran J, Palmer J, Badar T, Patnaik MM, Reichard KK, He R, Zepeda Mendoza CJ, Shah M, Orazi A, Arber DA, Pardanani A, Vannucchi AM, Hiwase D, Gangat N, Guglielmelli P. TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance. Am J Hematol. 2025 Jan 28. doi: 10.1002/ajh.27609. Epub ahead of print. PMID: 39873146.

4. Fischer M. Census and evaluation of p53 target genes. Oncogene. 2017 Jul 13;36(28):3943-3956. doi: 10.1038/onc.2016.502. Epub 2017 Mar 13. PMID: 28288132; PMCID: PMC5511239.

5. Xiang Zhou, Qian Hao, Hua Lu, Mutant p53 in cancer therapy—the barrier or the path, Journal of Molecular Cell Biology, Volume 11, Issue 4, April 2019, Pages 293–305, https://doi.org/10.1093/jmcb/mjy072

6. Yi K, Yang L, Lan Z, Xi M. The Association Between p53 Codon 72 Polymorphism and Endometrial Cancer Risk: A System Review and Meta-analysis. Int J Gynecol Cancer. 2016 Jul;26(6):1121-8. doi: 10.1097/IGC.0000000000000725. PMID: 27327151.

7. Garde-García H, Redondo-González E, Maestro-de Las Casas M, Fernández-Pérez C, Moreno-Sierra J. Biomarkers and intermediate-high risk non-muscle invasive bladder cancer: a multivariate analysis of three different cellular pathways with pronostic implications. Clin Transl Oncol. 2021 Apr;23(4):840-845. doi: 10.1007/s12094-020-02476-7. Epub 2020 Aug 24. PMID: 32839927.

8. Roshani D, Abdolahi A, Rahmati S. Association of p53 codon 72 Arg>Pro polymorphism and risk of cancer in Iranian population: A systematic review and meta-analysis. Med J Islam Repub Iran. 2017 Dec 27;31:136. doi: 10.14196/mjiri.31.136. PMID: 29951436; PMCID: PMC6014797.